Kura Oncology at Jefferies Conference: Strategic Advancements in AML

On Wednesday, 04 June 2025, Kura Oncology (NASDAQ:KURA) presented at the Jefferies Global Healthcare Conference 2025, showcasing its progress in acute myeloid leukemia (AML) treatment. The company highlighted promising data for its Menin inhibitor, Ziftomenib, and discussed future growth opportunities. While positive trial results and a robust cash position were emphasized, the competitive landscape and regulatory hurdles remain key challenges.

Key Takeaways

• Kura Oncology’s Menin inhibitor, Ziftomenib, shows promising data in AML treatment with a 23% complete response rate.
• The company is financially strong with $703 million in cash and potential milestone payments of $375 million from Keogh Kirin.
• A Phase 3 trial for Ziftomenib is planned for the second half of the year, aiming to consolidate two studies into one.
• Kura is exploring market expansion beyond AML into solid tumors such as GIST and breast cancer.
• The anticipated market opportunity for frontline AML treatments is estimated at $5 billion to $10 billion.

Financial Results

• Cash Position: Kura holds $703 million in cash, ensuring financial stability through to the commercialization of its AML program.
• Potential Milestone Payments: The collaboration with Keogh Kirin could bring an additional $375 million in near-term milestones.
• Funding Outlook: The company is fully funded through the frontline commercialization of its AML program.
• Market Opportunity: The total market size for frontline AML is estimated between $5 billion and $10 billion, with Kura potentially capturing $3 billion or more.

Operational Updates

• Regulatory Milestones: The PDUFA date for Ziftomenib is set for November 30, under Priority Review with Breakthrough Therapy Designation.
• Clinical Trial Progress: A Phase 3 trial initiation is planned for the second half of the year, combining two studies for efficiency.
• Clinical Data: The Phase 2 trial showed a 23% complete response rate and a median overall survival of 16.4 months.
• Commercial Readiness: Kura’s commercial team is poised for a swift launch upon approval.
• GIST Program: The COMMOD-fifteen study, combining Ziftomenib and Imatinib, has been initiated.
• FTI Program: Data on Tipifarnib in head and neck cancer and 2806 in renal cell carcinoma is expected in the latter half of the year.

Future Outlook

• EHA Presentation: Scheduled for June 12, focusing on frontline seven plus three combination data.
• Label Differentiation: Simplified dosing and combinability with other medications are anticipated advantages.
• First-Line Strategy: The Phase 3 trial design aims for broad label potential, integrating intensive chemotherapy and Venetoclax/Azacitidine regimens.
• Market Expansion: Kura is exploring indications in solid tumors like GIST and breast cancer, with potential applications in diabetes and other conditions.

Q&A Highlights

• Label Competition: The timing of approvals for Menin inhibitors is less critical than building relationships in this emerging market.
• Impact of FDA Changes: No expected changes to the accelerated approval pathway based on MRD negativity or complete response endpoints.
• Combination Therapy Strategy: Building extensive clinical data with Ziftomenib in various combinations to offer flexible treatment options.
• Market Opportunity: The frontline AML market is estimated at $5 billion to $10 billion, with significant potential in GIST if successful.

Readers are encouraged to refer to the full transcript for a detailed account of Kura Oncology’s presentation and strategic insights.

Full transcript - Jefferies Global Healthcare Conference 2025:

Roger Song, Senior Analyst, Jefferies: Alright. Welcome everyone to twenty twenty five Jefferies Global Healthcare Conference. My name is Roger Song, one of the senior analysts covers MidCab Biotech in The US. It is my pleasure to have the fireside chat with our next printing company, Kura Oncology, and then we have full crew here, CEO Troy, we have the commercial office Brian, and then CMO Molly. Welcome.

Troy Wilson, CEO, Kura Oncology: Thank you. Thank you.

Roger Song, Senior Analyst, Jefferies: Excellent. Alright. So off the press, we have this ASCO presentation, we all coming from Chicago a couple of days ago, and then what are the key highlights you want to have for the audience and who may not attend to that meeting and then although they should, so and then we can drive the drill down some of the details.

Troy Wilson, CEO, Kura Oncology: Sure, Roger. So, you to you and and Jefferies for putting on the conference. And we did do an analyst investor call immediately after ASCO if people want to listen to it, they can find that on our website. But in terms of what people should take away, I think most importantly, between our data and our competitors data, you now have two positive trials saying that this is a mechanism that works in AML. Right?

These these are likely to be real drugs. They’re likely to be approvable. We can talk about how they differentiate from one another and the labeling and so forth. But that’s I think an important step forward. You see a meaningful CR, CRH rate.

You see a in terms of twenty three percent for the phase two portion. You see importantly sixteen point four months median overall survival for the responders. That’s significant when you think about the overall survival in relapsed refractory leukemia typically being sort of three months. That says that these drugs these drugs are really doing something for those patients who respond. And that is all responders, not just CRCRH.

You see importantly, Zifdomenib is active in, you know, it’s consistent, consistently active. It doesn’t matter on the line of therapy. It doesn’t matter if the patients have had transplant. It doesn’t matter if they’ve had prior venetoclax. You’re seeing a consistent level of activity.

That’s all good. That’s all on the activity side. On the safety and tolerability, you’re seeing, know, importantly no myelosuppression differentiation syndrome that is well managed. We know that that is a class effect and yet with ZIFTO now, the physicians are able to manage it very effectively. You don’t have clinically meaningful QT prolongation.

We did have several instances of investigator assessed QT, but that is there are reasons for that, that are other explanations. There’s not really a QT signal there. And I think good combinability. It’s once a day oral dosing, very convenient and very easy to use. And I think two things Roger is, as we look at the benefit risk in the monotherapy, we think it compares potentially very favorable to our the one approved menin inhibitor.

And we’re I’ll put a plug in here now because I know we’re going to come back to it. We’re looking forward to sharing the frontline seven plus three combination data at EHA on June 12. And there, I think you’ll see why we keep stressing the importance of safety, tolerability, combinability, the absence of myelosuppression. These agents are going to be used in combination and that’s where you’re really going to start to see I think what Ziftaminib can do combination context. So, those are the key takeaways.

We now have a PDUFA date of November 30 and we’re just super excited to keep moving the program forward.

Roger Song, Senior Analyst, Jefferies: Well said. I don’t think in any ambiguity there, lay line INR, NPM1 AML data is absolutely impressive in terms of the details and the consistency, the differentiation on the safety profile for sure is very clear. So, before we talk about the first line, which should the next focus, but you have the PDUFA date, November 30, and the priority review with BTD, that’s the only and the first BTD for this setting. How should we think about you mentioned you give us some teasers that differentiate differentiation in the label, right, so how should we think about this profile you can expect to the label different from other, you know, MEN inhibitor, and then we’ll talk about the commercial dynamic for that setting before we move on to the first line.

Brian casey, Commercial Officer, Kura Oncology: Sure. Would you like me to do the the differentiation as Sure. So and thanks, Roger, for the question. Yeah. So we think that, you know, the data and as we said that that we presented earlier this week and the data we’ve seen some some of our competitors, from an efficacy perspective, are largely kind of price of entry, I think, into this space.

You know, CRC rates, duration response, things like this are are based on feedback we’ve heard seem to be, you know, comparable and and I think an important step for getting product available for patients in this setting. I do think within the label as hopefully as we get into some of the ability to combine ability to combine with concomitant medications, not have to dose adjust. Those are some important things that I think we we think we’ll we’ll be able to articulate in the label. Articulate in the label. The safety profile, think, also as being safe is going to be important.

And and, you know, some of the work we’ve evaluated as a as a pre commercial team right now is try to understand, like, where some of those differentiation points may be. Something which may sound simple, but once daily dosing is meaningful. And I think that’s been meaningful from what we’ve heard from both physicians, their practices, and their patients without requirement of potential QTC monitoring for or cardiac monitoring for QTC prolongation, things like that as well.

Molly peters, CMO, Kura Oncology: And and the dosing’s also vastly simplified from what we what we expect to see. The dosing will be vastly simplified than what is currently in the revivemena label due to having to consider so many drug drug interactions. So, think all around the safety and the combinability, even as a monotherapy shines through.

Roger Song, Senior Analyst, Jefferies: Yeah, and then the QT, the cardiac monitoring, so that’s another thing that we see pretty common. And we clay for at least a month and then afterwards it’s still monthly monitoring. That’s forever, and on your treatment.

Troy Wilson, CEO, Kura Oncology: And just while we’re on that point, Roger, if in the absence of of a competitor, you know, what we hear clearly from physicians is, I would do that. Right? I would do I would do cardiac monitoring if I had no other option. But if there is another option where you don’t need it, then most of them say, well why would I do cardiac monitoring? That’s important in the relapsed refractory setting.

Becomes very important again, as we’re thinking about how can we keep these on continuation therapy as we go earlier. That’s what’s really I think going to pull through. We’re prosecuting the regulatory and commercial in the relapsed refractory, but also as you’ll see again at EHA having experience in the frontline setting where when you look at those patients going out on the swim lanes, think about whether or not they have to come in monthly for cardiac monitoring or dose adjustments or other things. That’s again where I think our safety and tolerability profile will pay dividends.

Roger Song, Senior Analyst, Jefferies: Yeah, I totally agree. And then we know oncology, the competitive space and also for the incidence, you know, patient. I understand for one of the competitor, they got approval in other subgroup, not in the this subgroup, but we don’t know if they will get before or after you get approval, but it would I think the timeline will be similar. I don’t think you have a significant first mover advantage for that population, although, you know, I don’t know if it’s right or wrong to say some off label use in the beginning while you’re waiting for the new label. So maybe on that point, so what’s the feedback you are getting from the physician, say, okay, I have a drug, I may have some experience, and I may have something that I start to use, but I have two approval upcoming, and how I’m to switch those patient, my new patient to use that?

Brian casey, Commercial Officer, Kura Oncology: Sure. Yeah, thanks for the question. I think from the from what we’re hearing from physicians, they’re excited that there are options now for a Menin inhibitor, and multiple Menin inhibitors on the baron kit, I think, may be good for them. I think they’re starting to get some experience, and we’re happy to see that a menin inhibitor in this space is something that offers that benefit for patients. I think whether or not we become the first approved therapy or the our competitor becomes the first approved therapy, I don’t think is going to be as big of an impact in this space, given that both of us are still new to this, you know, even if there’s a few months or a year before we get our first approval.

We’re still new to this space, and we’re still, you know, kind of building our relationships, other than those that really started to build out strongly with our clinical design our clinical programs. So Molly and the team have really kind of built a robust clinical program that’s given a number of investigators experience with Ziptaminib, and we think that will helpful for us as we transition into the commercial setting. We’re also setting up our commercial team to, you know, recognize that AML is a competitive space. We’re planning to be ready for, day one to get product out and to really start to engage with those customers as soon as possible and do what we’re able to do compliantly to start to engage with physicians once the sales team is on board and preparing profile those physicians. So we feel pretty confident that we’ll be ready for that launch whenever that may come from the FDA.

And we’re sure that we’ll ensure that we’ll be able to get product out to patients as quickly as possible

Roger Song, Senior Analyst, Jefferies: too. Awesome. Alright. Good. So, we should move on to talk about the even much bigger opportunity for the first line.

I think Troy, you already gave us some teaser in terms of upcoming EHA presentation. Maybe just give us a little bit more in terms of what should we expect, right, So, talk about the plasma for the durability and then maybe some of the other aspects that we should focus on MRD and then any other data point we should focus?

Molly peters, CMO, Kura Oncology: I think some of the biggest things you should look at, of course, we love a good response rate. We’ve had a very robust response rate in this patient population. We’d want to see a consistency of that. I want to remind you that you’re going to see not just our Phase Ib patients, not just the expansion patients, We’ll also see patients that came on during the Phase Ia. So clearly they’ve been on trial a lot longer than these later patients will be showing you.

So you’ll be able to see their story, their patient story, their durability, how they’re doing, you know, forty plus, fifty plus weeks onto treatment. And you’ll see, through the swimmer’s plots, that they have actually stayed on treatment. You’re going to be able to see the MRD, which I think is very important, and that will, of course, still evolve over time. But a very important point to look at, which speaks again to safety and combinability, is time to count recoveries. So the time it takes for these patients to actually get back to their, quote unquote, norm, where they’re not at risk for infections to that extent, where they’re not at risk for bleeds.

Many drugs, when you combine them, you get compounded myelosuppression. And we’re very pleased to be able to show you that we do not believe that is the case with Ziptovenib therapy.

Roger Song, Senior Analyst, Jefferies: Got it. Okay, very good. I think that’s And another aspect is you are the first one to report a seven plus three intensive chemo combination, while other, you do have other many inhibitor, but they only in the Venaza combination, and then why is that, and then why it matters?

Troy Wilson, CEO, Kura Oncology: Maybe just a correction. We had intensive chemotherapy phase one data at ASH twenty twenty four. Think J and J did as

Roger Song, Senior Analyst, Jefferies: well. So,

Troy Wilson, CEO, Kura Oncology: we’ve announced as part of COMMOD 17 that we’ll be doing a randomized phase three in that setting. We haven’t yet seen, Roger to your point, we haven’t seen any other of the sponsors of menin inhibitors yet announce their registration plans in the intensive chemotherapy setting. That’s different than what’s happened in the Venase setting.

Roger Song, Senior Analyst, Jefferies: Yeah, got it. Okay, and then the reason you can move so fast is because have the phase one data and then also the profile, the safety profile is good enough to do the combination, and then also the phase three design is very creative, and then to be able to combine those two regimen together to do the pivotal.

Troy Wilson, CEO, Kura Oncology: Yeah. That’s right.

Roger Song, Senior Analyst, Jefferies: Okay. Good. And then, so maybe just for the data seven plus three, we’re going to have some data at the EHA, and then also you will, you also continue to do the expansion for the VENESA, that data will come in a bit later, potentially ASH. And then what should we expect from there, similar story or any particular points you want us to focus?

Molly peters, CMO, Kura Oncology: Similar story, but, you know, this will be we’ll show probably the relapsedrefractory data, not definitively yet, but we’ll make this will be the first glance at the frontline venetoclax azacitidine data. So the patients won’t have been on for as long as maybe our Phase 1a seven plus three patients, but still you’ll start to see the trend in time to response and time on treatment, the ability to keep these patients on treatment even if they’re modifying the backbone durations. And again, time to MRD negativity, time to count recoveries will also be extremely significant. Vaneza is, you know, I think every institution uses it their own way, because it’s so myelosuppressive. They want to use less of it whenever possible.

And we have designed a study that hopefully allows them to do that for the benefit of the patients and while still getting full coverage of their disease with the Menin inhibitor on board.

Roger Song, Senior Analyst, Jefferies: Okay, got it. Okay, then that’s your phase one expansion with that data supporting your plan into the pivotal phase three. As I mentioned earlier, so you have pretty creative free design for the phase three. The investor always ask, with all the FDA change, so the confidence level you still can stick with that accelerator approval potential pathway for your Phase III, anything change based on your interaction with the new FDA?

Molly peters, CMO, Kura Oncology: No, we don’t expect any changes. And we haven’t seen any turnover or anything like that in our particular review team. So we wouldn’t expect like changing perspectives to to play any part in it at this point.

Troy Wilson, CEO, Kura Oncology: Yeah. I think the the hurdle that that we were able to get over or the field has gotten over, Roger, is relating MRD negativity or, you know, in the case of intensive or CR in the case of non intensive to benefit and to a survival as a surrogate for survival. We don’t see that changing. That’s I know there’s been some discussion around MRD negativity, but that is more in the context of multiple myeloma. And the issue wasn’t the adequacy of the surrogate endpoint.

It was that you had patients who have the potential to stay on therapy for ten years. That’s not the case in AML. AML is patients are in desperate need of these therapies. I think there’s a recognition that we need to do all we can to get patients therapy. There will be survival based endpoints for both of the phase threes that offer the protection ultimately to the patient community that there is a survival based benefit.

So, we don’t see any change coming from any of the health authorities.

Roger Song, Senior Analyst, Jefferies: Yeah, got it. Yeah, so we’re just coming from ASCO, still the pretty clear desire to build a correlation between the MRD negativity to the survival, and then you have all the mounting evidence to support that correlation. I think that’s the That may lead to this kind of endpoint design. Yeah. That’s correct.

Okay, good. All right. And then, so you guided that you will start the trial second half and then between now and then, so what’s going to supposed to happen before you can start the trial? I’m not trying to press you. I know it’s still on track, right?

Molly peters, CMO, Kura Oncology: Right now, it’s all about operationalizing. So every site has to be contracted with, and it has to go through their IRBs, etcetera. So that’s what we’re currently doing. Obviously, the protocol has been final, been with sites and everything’s moving along quite well.

Troy Wilson, CEO, Kura Oncology: Yes, something may not be appreciated. I’ll just call it out Roger because I think it was a very clever idea by Molly. We’re combining two phase threes under a single protocol. And where that really helps us is at this point in terms of operationalizing the trial. So there’s contracting, there’s budgeting, there’s IRB or ethics review.

We don’t have to do that twice for two phase threes. We’re doing it a single time and you now have a protocol where with a fairly narrow exception, almost any patient who presents at the clinic is eligible to come on the 17 protocol. So we have a lot of operational synergy and that’s what allows us to be competitive and we think move more quickly than our competitors in the field in the frontline setting.

Roger Song, Senior Analyst, Jefferies: Maybe just how big a deal you can combine them in a relatively in parallel fashion to be able to get the label pretty broad in the first line, and then based on your feedback from the investigator or advisor say, okay, if I get that label, I will use the drug more or less than the people with a narrower label.

Molly peters, CMO, Kura Oncology: Are you talking about in the combination setting?

Roger Song, Senior Analyst, Jefferies: Yeah, combination.

Molly peters, CMO, Kura Oncology: Intensive. Yeah, mean, in mind the labels will come in waves. So, you know, should everything go as planned, the initial accelerated approval will be for MPM1 mutants. And then we’ll add on the overall the full approval with all patients. And similar for Venesa, it’ll be initially the CR approval with full approval coming after that.

The label is just one piece of data that treaters have when they’re using, and they treaters are always looking to revolutionize the way they’re treating their patients. So they are always wanting to do new ISTs, which we have a lot of those going on, so that they can try out new combinations, or maybe some of their pet combinations that they think are good. So the label will be wonderful, but will they always stick to it? No. They’re going to treat the way they think is best for their patients.

Troy Wilson, CEO, Kura Oncology: Yeah, I was going to say that goes back, Roger, to where we’re stressing safety, tolerability, convenience, once a day dosing. These physicians are very sophisticated. Treatment pattern vary by institution. Many of them use venetoclax, but we’ve done two things. Again, Molly spearheaded this.

One is we have a broad foundation of both CURA sponsored and investigator sponsored studies with Zifdomenib in different combinations. So including intensive chemo, Venaza, but also things like Flagida, low dose EraC, gilteritinib, to give we’ll eventually publish that data. That’ll give clinicians experience with how to use Zifdomenib safely. And then this growing body of safety and tolerability data gives them the flexibility to use the drug as they see fit. Ultimately, that’s what they’re licensed to do and that’s what we want to enable them to do.

So to Molly’s point, it’s less about, yes, the breadth of the label is really our ability to promote. But this growing body, when we’ve made, as you can tell, a considerable investment in development, we think that’s really going to position civtomenib to be best in class.

Roger Song, Senior Analyst, Jefferies: Got it. And then understanding your intensive chemo cohort study, you do have the maintenance therapy component. So that part is likely coming along with the accelerated approval or that’s maybe the later on.

Molly peters, CMO, Kura Oncology: That’ll be along with the full approval because it’ll come after they’ve finished consolidation and the accelerated approval endpoint is measured prior to consolidation.

Roger Song, Senior Analyst, Jefferies: But it will, it designed for to be in the label once for the final Absolutely. Result. Okay. Got it. Alright, let’s talk about the market opportunity.

I think you give us some good assumption for the future first line AML, and then maybe talk about the overall market, and then how ceftomannab will play into the future market.

Brian casey, Commercial Officer, Kura Oncology: In the frontline setting? Yeah, in frontline Sure. So, I think the way we look at this is that, you know, there are approximately twenty thousand patients diagnosed with AML a year. We think about half of those patients may be eligible to receive a menin inhibitor, either if it’s, you know, in these combinations with that have KMT2A and PM1 mutations or FLT3. If you think that if you split those patients somewhere roughly half of each half of the patients may go into intensive therapy, the other half may go to non intensive.

The intensive therapy patients, we see there may be opportunity for patients to receive ZiftoMenib for, you know, twelve to eighteen months within that. On the non intensive, it may be, say, twelve to eighteen months. With those up, you know, kind of putting those together with the premium pricing you may get it within AML, that could lead you to a between, you know, dollars 5,000,000,000 to $10,000,000,000 market in that space. We think that with our profile and as the, you know, the studies that Molly’s been kicking off and we hope to get forward to get an approval, we could easily capture half of that. So it’s, you know, $3,000,000,000 potentially or more.

And and, you know, the confidence, I think, that we have and will hope to continue to see with the data is that the tolerability of being able to put patients on therapy and keep them on is really where you can see a transformation of AML into a where you could have billion dollar

Roger Song, Senior Analyst, Jefferies: products. That’s great. Okay. Alright. So I understand you have this lead indication as AML, but safe to mannib or mann inhibitor potentially can do more.

Right? So the bigger, even bigger market opportunity is the the solid tumor. I know you are doing the GIST and then some other combination as well. So tell us about the, you know, the cancer expansion on the cancer side, and then also maybe on the non cancer side for the whole mannan franchise.

Troy Wilson, CEO, Kura Oncology: Yes. So, we initiated earlier this year the COMMOD-fifteen study, which is the combination of Zifdomenib and Imatinib in patients with advanced GIST. That we think is the first example, Roger, of we may see multiple examples where a menin inhibitor plays an important role in combination. You don’t expect a menin inhibitor to really have meaningful activity in solid tumors as a monotherapy, but what you’re doing is you’re targeting epigenetic control of other oncogenes. So in the case of GIST, as it turns out, KIT GIST tumor cells require KIT overexpression.

That overexpression is regulated by menin. And so by blocking the menin interaction in combination with attacking the tumor cell from two different directions. You’re blocking the catalytic activity of KIT, and you’re down regulating the epigenetic expression. GIST tumor cells are oncogene addicted to KIT, and so when you do that, you can actually push those tumor cells over into apoptosis. We see activity of Ziftametib with all KIT inhibitors in sort of every line.

This is pre clinically. We’re now evaluating that in the that in the clinic. It’s early days. It’s in dose escalation. But the significance of that is imatinib is the approved standard of care.

It’s well accepted. It’s well liked in front line GIST. But sixty percent of patients develop resistance to imatinib. So if we could deepen the responses, if we could make those responses more durable, you could imagine now you’re using Ziftamenib right from the beginning on top of Imatinib, you could go two years, potentially three years. That opportunity could be as significant as either the intensive or non intensive AML setting.

We haven’t guided yet to data from GIST. We’re still early in dose escalation, but the preclinical data is stunning and the GIST KOLs are excited to have a new mechanism of action. We met many of them at ASCO and they’re just thrilled. Beyond that, there are other opportunities. One that is quite public is the combination of a menin inhibitor and a cat 6a inhibitor in breast cancer.

Breast is a you know, it’s very dynamic field, so I think you have to be careful. But it’s another example where Menin on its own, maybe not enough, but when you get into the context of synergy with another therapeutic target, it becomes quite significant. We will likely pursue GIST with Zifdomenib. Anything else, Roger, we would do in either solid tumors, diabetes, or other indications, we would probably do with a next generation menin inhibitor, distinct from ZIFTOMENNIM.

Roger Song, Senior Analyst, Jefferies: Got it. Okay. Very good. Couple more minutes, and then you do have another side of the pipeline, which is the FTI franchise and the TPE and 02/1400. So, tell us what’s the status of that when we potentially can see some data?

That could potentially be even if not bigger, if big at the maintenance side. Side?

Troy Wilson, CEO, Kura Oncology: Yeah, thanks for mentioning that. So, the opportunity, it’s interesting. The farnesyl transferase inhibitors are conceptually similar to the menin inhibitor, right? Neither of those are an oncogene. They are proteins that regulate other genes or other proteins.

In case of an FTI, you are blocking farnesylation. This is a post translational modification on other proteins. It’s, think of it as it’s important for drug resistance. Whether you look at KRAS inhibitors, PI3 kinase inhibitors, tyrosine kinase inhibitors pre clinically, we see pretty consistent activity, but inevitably most of those patients develop resistance and unfortunately go on to pass away from their disease. It turns out they all have a common vulnerability, and that is a choke point in the target of rapamycin, TOR.

TOR is regulated by a protein called REB. REB is RAS homolog expressed in brain. REB is a uniquely farnesylated protein. And what we see is we, pre clinically, again, we can give an FTI, farnesyl transferase inhibitor, whether tipifarnib or our new compound two thousand eight hundred and six, with these targeted therapies and rescue them in some cases, in the cases of resistance, or drive deeper and more durable responses. So it’s an interesting opportunity Roger, to your point, in that this is for a long time been an area of high interest.

How can we find a target that is combinable with other solid tumor targets to drive better clinical benefit for patients. Later this year, in the second half, we’re going to show you four I think it’s four different no, three different cohorts. We’ll show you tipifarnib plus alpelisib in PIK3CA mutant head and neck cancer. And then we’ll show you two cohorts, a monotherapy of two thousand eight and six and a combination of two thousand eight hundred six, which is our second gen FTI plus cabozantinib in renal cell carcinoma. There’s a lot of development going on there.

We look forward to sharing that data again in the second half of the year potentially at ESMO.

Roger Song, Senior Analyst, Jefferies: Excellent. All right. Just last a couple of seconds for the cash because you do have a significant cash to support the whole AML program and then with the partner with KK?

Troy Wilson, CEO, Kura Oncology: Yeah, so we had $7.00 3,000,000 in cash as of the end of the last quarter. We have, I think we’re eligible for an additional $375,000,000 in near term milestones under our collaboration with Keogh Kirin. We’ve guided Roger that we should be fully funded through in the AML program through to frontline commercialization. We won’t able to do late stage development, for example, in the FTIs, but if the data justifies doing that, I think there will be a lot of value for patients and for shareholders. And so between AML, GIST, the FTI program, diabetes, there’s a lot of value drivers over the next six to twenty four months.

Roger Song, Senior Analyst, Jefferies: Excellent. Great. Thank you for the team being there with us this afternoon. Thank you everyone for listening.

Troy Wilson, CEO, Kura Oncology: Thank you. Thank you.

Brian casey, Commercial Officer, Kura Oncology: Thank you.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.